Technology
Health
Biotechnology

Outlook Therapeutics

$2.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.83 (42.35%) Today
+$0.01 (0.36%) After Hours

Why Robinhood?

You can buy or sell OTLK and other stocks, options, ETFs, and crypto commission-free!

About

Outlook Therapeutics, Inc. Common Stock, also called Outlook Therapeutics, is a clinical-stage biopharmaceutical company. Read More The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.

Employees
56
Headquarters
Cranbury, New Jersey
Founded
2010
Market Cap
20.85M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.00M
High Today
$2.89
Low Today
$2.23
Open Price
$2.39
Volume
11.14M
52 Week High
$10.96
52 Week Low
$0.85

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2016 IPO

Earnings

-$0.70
-$0.62
-$0.54
-$0.46
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$0.58 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.